U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07332767) titled 'Myocardial Energetic Restoration in the Treatment of Obstructive Hypertrophic Cardiomyopathy' on Dec. 29, 2025.
Brief Summary: Hypertrophic Cardiomyopathy (HCM) is the most common inherited heart condition, where the heart muscles can thicken to the point of obstructing blood flow out of the heart. This condition is associated with a chronic state of energy loss in the heart muscle.
Till more recently, a new class of medication (cardiac myosin inhibitors) have been introduced to directly target the heart muscle proteins (sarcomeres) to reduce the strength of contraction and relieve obstruction of blood flow out of the heart. While ...